Detalles de la búsqueda
1.
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.
J Infect Dis
; 227(8): 939-950, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36348617
2.
Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
Clin Infect Dis
; 73(7): e1885-e1892, 2021 10 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32916708
3.
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19).
Lancet
; 392(10143): 232-243, 2018 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-30047376
4.
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
J Infect Dis
; 218(4): 633-644, 2018 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29669026
5.
Pharmacokinetics and pharmacodynamics of boosted once-daily darunavir.
J Antimicrob Chemother
; 69(10): 2591-605, 2014 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-24951533
6.
Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
Int J Clin Pharmacol Ther
; 52(9): 805-16, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25109510
7.
Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial.
AIDS Res Ther
; 11: 39, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25926858
8.
Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption.
Cell Rep
; 43(6): 114344, 2024 Jun 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-38850529
9.
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy.
NPJ Vaccines
; 9(1): 89, 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38782902
10.
Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.
Clin Gastroenterol Hepatol
; 11(2): 193-5, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23159528
11.
Effect of darunavir on lipid profile in HIV-infected patients.
HIV Clin Trials
; 13(5): 256-70, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-23134626
12.
Acute HIV-1 infection viremia associate with rebound upon treatment interruption.
Med
; 3(9): 622-635.e3, 2022 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35870446
13.
Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
Vaccine
; 39(22): 3081-3101, 2021 05 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33676782
14.
Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees.
Open Forum Infect Dis
; 8(1): ofaa606, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33511233
15.
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lancet HIV
; 7(10): e688-e698, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33010242
16.
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Lancet HIV
; 7(6): e410-e421, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32078815
17.
Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption.
Nat Med
; 26(4): 498-501, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32235883
18.
Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
Antivir Ther
; 14(6): 859-64, 2009.
Artículo
en Inglés
| MEDLINE | ID: mdl-19812449
19.
Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Lancet
; 370(9581): 49-58, 2007 Jul 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-17617272
20.
Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
Antivir Ther
; 21(4): 317-27, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26566161